Clofarabine + Cytarabine + Decitabine
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Trial Timeline
Oct 1, 2008 → Jan 1, 2015
NCT ID
NCT00778375About Clofarabine + Cytarabine + Decitabine
Clofarabine + Cytarabine + Decitabine is a phase 2 stage product being developed by Eisai for Acute Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00778375. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00778375 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia